The debate over the future of thermal cures in France has reached a critical juncture following a decisive vote in the Senate on Friday, November 13, 2026. Lawmakers across the political spectrum voted unanimously to adopt six amendments designed to block any sweeping changes to the state reimbursement rates for thermal cures until the High Authority for Health (Haute Autorité de Santé, or HAS) completes its long-awaited scientific evaluation. This legislative push offers a temporary reprieve to roughly 470,000 patients who rely annually on hydrotherapy to manage chronic conditions. The government’s initial proposal sought to trim the social security budget for 2027 by drastically cutting the national health insurance (Assurance Maladie) coverage for thermal treatments from 65% down to 15%. While the Senate’s united front has successfully stalled the controversial measure for the time being, the broader economic and healthcare implications of the proposed reform continue to fuel intense national debate.

Background Context and the Proposed Financial Shift

Thermal cures have long held a unique position within the French healthcare framework. Prescribed by physicians for specific chronic ailments—most notably rheumatology, respiratory disorders, and dermatological conditions—these treatments combine mineral-water hydrotherapy with medical supervision. Currently, standard convention treatments are reimbursed at 65% of the negotiated baseline tariff by Assurance Maladie, provided patients meet strict administrative and medical criteria.

As part of ongoing efforts to rein in public spending and identify substantial savings within the social security financing bill (PLFSS) for 2027, the executive branch targeted these reimbursements. Government budgetary estimates indicated that shifting the financial burden from the state to supplementary health insurance providers (mutuelles) would generate approximately 200 million euros in savings. However, this transfer of costs raises acute concerns regarding equity in healthcare access. Under such a restructuring, individuals holding limited supplemental health insurance policies, or those whose contracts do not cover thermal care contingencies, would face steep out-of-pocket expenses.

Chronology of Events Leading to the Senate Vote

The friction between the government and parliamentarians regarding the valuation of thermal cures did not materialize overnight. The timeline of events highlights a sustained legislative tug-of-war over the clinical and economic relevance of hydrotherapy:

  • February 2026: The Minister of Health formally seizes the High Authority for Health (HAS), requesting a comprehensive scientific assessment of the medical service rendered (service médical rendu, or SMR) by thermal cures. The mandate directs the authority to review existing clinical literature and evaluate therapeutic outcomes.
  • Late 2025 – Early 2026: Preliminary budgetary discussions for the social security financing begin to signal government intent to scale back state participation in thermal cure funding, triggering early warnings from medical professionals and regional stakeholders.
  • November 13, 2026: Facing potential legislative pressure, the Senate convenes to debate the 2027 budget components. Six identical amendments are introduced by senators from various political groups to tie any reimbursement modifications directly to the outcome of the HAS report.
  • November 13, 2026 (Evening): The Senate passes all six amendments without a single opposing vote, establishing a formal legislative barrier against immediate de-reimbursement.
  • Late 2027 (Anticipated): The Haute Autorité de Santé is expected to publish its final, definitive scientific review regarding the medical efficacy of thermal treatments.

The Central Role of the High Authority for Health

At the core of the parliamentary opposition lies a demand for evidence-based policymaking. Senators from disparate political alignments argued that enacting a steep financial penalty on patients before verifying the clinical utility of the treatments is fundamentally premature. The debate is not necessarily centered on a permanent guarantee of the 65% rate, but rather on the principle that health policy decisions must await scientific validation.

The evaluation requested from the HAS in February 2026 requires an exhaustive meta-analysis of medical literature concerning the long-term benefits of thermal cures on chronic disease management. Because clinical trials and observational studies of this nature require extensive methodological review, experts project that the definitive opinion will not be made public until late 2027. Consequently, implementing a drastic budgetary reduction in 2027 would circumvent the very scientific findings the government commissioned.

Reactions and Perspectives from Stakeholders

The unanimous vote in the Senate reflects an alliance of regional interests, healthcare advocates, and political groups sensitive to the socio-economic fabric of rural and thermal-dependent communities. Representatives from spa-heavy regions, including the Pyrenees, the Massif Central, and the Alps, voiced strong support for the amendments, emphasizing that thermal towns operate as critical economic hubs.

Beyond the direct medical implications for the 470,000 annual curistes, local economies are deeply intertwined with the thermal industry. Hotels, restaurants, local commerce, and specialized medical support staff depend heavily on the influx of seasonal visitors. Industry representatives have warned that dropping the state reimbursement to 15% could lead to a catastrophic drop in attendance, threatening the financial viability of numerous establishments and endangering thousands of regional jobs.

Conversely, defenders of the budget reduction point to the necessity of prioritizing state expenditures amid persistent national deficits. From a strictly macroeconomic viewpoint, proponents argue that public health funds should be channeled toward treatments with unambiguous, immediate pharmaceutical or surgical imperatives, leaving complementary insurers to manage comfort-oriented or traditional therapies. Nevertheless, the speed with which the government’s proposal was rebuffed underscores the political sensitivity of cutting benefits perceived as essential by an aging population managing chronic illnesses.

Broader Implications and Future Outlook

Despite the decisive nature of the Senate’s intervention, the legislative battle over thermal cure reimbursement is far from resolved. The parliamentary process for the 2027 social security budget involves multiple readings across both chambers of Parliament. Amendments passed in the Senate must navigate subsequent legislative hurdles, and potential compromises during joint committee meetings could alter the final text.

Furthermore, legal and regulatory experts note that modifications to reimbursement rates can occasionally be handled through regulatory decrees rather than primary legislation alone. This dynamic means that the ultimate fate of the thermal sector will depend on both the outcome of the budgetary legislative cycle and the eventual regulatory posture adopted by the executive branch.

For the hundreds of thousands of patients who schedule their annual therapeutic stays months in advance, the current climate remains one of cautious uncertainty. While the Senate has provided a crucial legislative shield for the immediate future, patient advocacy groups advise curistes to review their specific health insurance contracts and communicate directly with their local primary health funds (Caisses Primaires d’Assurance Maladie) to understand their current coverage levels. As the medical community awaits the definitive verdict from the Haute Autorité de Santé in late 2027, the future balance between public fiscal austerity and patient access to traditional thermal medicine hangs in a delicate equilibrium.

By Sagoh

SanteNews

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.